Christopher M. Adams, MD, PhD – Founder & President
Chris Adams has served as President and CEO of Emmyon since 2012. He is a Professor of Medicine, Clinician Investigator, and Research Chair of the Division of Endocrinology, Diabetes, Metabolism and Nutrition at Mayo Clinic in Rochester, Minnesota. His research focuses on mechanisms and treatment of muscle atrophy and diabetes. His clinical practice focuses on the care of patients with diabetes and other endocrine disorders.
Scott M. Ebert, PhD – Vice President – Biology
Scott Ebert is an accomplished skeletal muscle biologist who joined Emmyon in 2013. He is an Assistant Professor in the Division of Endocrinology, Diabetes, Metabolism and Nutrition at Mayo Clinic in Rochester, Minnesota. His research focuses on mechanisms and treatment of muscle atrophy and diabetes.
John J. Talley, PhD – Partner & Vice President – Chemistry
John Talley has led the medicinal chemistry program at Emmyon since 2012. He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents. His inventions include the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil® and the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®. The medicines invented by Dr. Talley have improved the health of millions of patients and generated over $40 billion in sales to date. He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. In 2015-2019 and in 2021, Dr. Talley was named to The Medicine Maker Power list, which recognizes the world’s most influential people in drug discovery and development.